Articles tagged with Target Mrna
Researchers explore potential synergies between chemotherapy, cannabinoids, and intermittent serum starvation in treating colorectal cancer. Combining these therapies could create a strong synergy by depriving cancer cells of glucose, making them more susceptible to treatment.
Researchers have created a comprehensive database of protein changes in mice tissues due to aging, providing new insights into age-related diseases. The study reveals proteins that increase with age and improve understanding of the molecular mechanisms underlying aging.
Researchers at POSTECH have identified GLUT3 as essential for the suppressive function of regulatory T cells in tumor microenvironments, which can be targeted for cancer immunotherapy. The team's findings highlight the critical role of GLUT3 in regulating protein modifications that sustain immune suppression within tumors.
Researchers have discovered a new strategy to overcome docetaxel resistance in advanced prostate cancer patients, which may improve the efficacy of chemotherapy and prolong overall survival. The approach involves inhibiting cholesterol and lipid biosynthesis, reinducing sensitivity to the drug docetaxel.
Researchers successfully delivered anti-cancer ASO molecules to lung tumor sites using human red blood cells, demonstrating potent anti-cancer effects against NSCLC. The approach utilizes EGFR-targeting moieties to home in on cancerous cells, offering a potentially powerful treatment modality for personalized cancer medicine.
Researchers from Brazil's Center for Research on Redox Processes in Biomedicine found that high blood sugar can cause thrombosis by altering endothelial function and promoting platelet adhesion. They identified a specific molecular mechanism involving protein disulfide isomerase A1 as a key regulator of this process.
Researchers at Kumamoto University identified G-quadruplexes as a central role in promoting alpha-synuclein aggregation, leading to neurodegenerative diseases. Inhibiting G4 assembly may prevent the onset of synucleopathies and position it as a promising target for early intervention.
Researchers at MD Anderson Cancer Center have made significant advancements in understanding tissue regeneration, with a focus on epigenetic regulation and retrotransposon suppression. MicroRNAs have also been identified as potential biomarkers for COVID-19 severity in cancer patients, while a novel protein complex drives lung regenera...
Researchers discovered a gene-mutation pathway that can lead to targeted therapies for blood cancers. The TET2 gene's enzymatic activity regulates chromatin state and leukaemogenesis, providing new therapeutic targets.
Researchers at U of T have discovered that C2H2 zinc finger proteins, which primarily bind to DNA, also regulate RNA processing through various mechanisms. These proteins modify mRNA, controlling its length and altering it after transcription.
Researchers at Nagoya University developed an innovative synthesis technology to produce high-purity, fully chemically synthesized mRNA. This breakthrough cuts down the production time and can be used to address concerns about purity and speed in mRNA vaccine development.
A new proteomics study explores the relationship between protein and transcript levels in young-adult and old mice bones. The research identifies key targets associated with bone mineral density and aging, shedding light on protein-specific changes that occur with age.
Mayo Clinic scientists created mini brain models in a dish that closely match key features seen in the brains of patients with Lewy body dementia. The team identified four potential drug compounds that may offer approaches to treating the disease.
A new study found that common breast cancer treatments, including chemotherapy, radiation, and surgery, can increase expression of aging markers in breast cancer survivors. The study suggests that these treatments can have a more extensive impact on the body than previously thought, leading to accelerated biological aging.
Researchers at Houston Methodist are working on a national consortium to develop vaccines against two common and destructive strains of herpesviruses. The project aims to create prophylactic and therapeutic vaccines using a computational toolkit that could transform vaccine development.
A study found that doxycycline post-exposure prophylaxis (doxy-PEP) did not significantly alter the overall composition of gut bacteria in individuals who took it for six months. However, the researchers noted signs of resistance building against tetracycline, a class of antibiotics to which doxycycline belongs.
Researchers at the University of São Paulo developed a synthetic peptide that mimics the ACE2 receptor, blocking SARS-CoV-2 invasion and reducing inflammation in human lung cells and mice. The peptide could be customized for every variant, offering a fast-acting molecular shield against the virus.
A research team developed an RNA-based sensor platform that can regulate gene expression in bacteria, mimicking natural biological interactions. The START platform enables tunable control over sensor response and detection of various molecules, including drugs and proteins.
Researchers at the University of Pennsylvania School of Engineering and Applied Science have discovered a novel means of directing lipid nanoparticles to target specific tissues. By incorporating siloxane composites into ionizable lipids, they were able to achieve tissue-specific delivery, particularly to the liver, lungs, and spleen.
Researchers at Tel Aviv University discovered that aneuploid cells, which have an abnormal number of chromosomes, are more susceptible to certain types of anticancer drugs. The studies found that disrupting the MAPK pathway increases the sensitivity of these cancer cells to chemotherapy.
A Cornell University-led collaboration has developed a machine learning model that uses cell-free molecular RNA dregs to diagnose pediatric inflammatory conditions, including Kawasaki disease and Multisystem Inflammatory Syndrome in Children. The diagnostic tool accurately determines the patient's condition while monitoring organ health.
Researchers at Nagoya University have developed a method to chemically alter siRNAs, reducing off-target effects and improving the safety of siRNA drugs for genetic therapy. By modifying the seed region of siRNAs with formamide, they achieved suppression of off-target effects with higher efficiency than existing chemical modifications.
Experts propose a series of scientific principles and experimental approaches to assess potential carcinogenicity of gene therapies. Data transparency is crucial, with publicly accessible data from viral integrations site studies and clinical settings.
Researchers have shown that repeated administration of lipid nanoparticle-encapsulated mRNA therapy significantly extended survival and reduced serum leucine levels in a mouse model of maple syrup urine disease. The treatment approach may represent a potential long-term universal treatment for MSUD.
Researchers have developed a nanodrug that targets miR-10b, a small noncoding RNA implicated in cancer cell invasion and proliferation. The study shows that inhibiting miR-10b reduces the stemness of breast cancer cells, supporting dedifferentiation as a potential therapeutic mechanism.
Researchers have developed two new methods to produce circular RNAs, which can silence genes and serve as templates for making therapeutic proteins. These circular RNAs display enhanced stability and biological activity in heart muscle cells and neurons.
Researchers developed a treatment approach using lipid nanoparticles to deliver mRNA therapy for MSUD, extending survival and reducing serum leucine levels. The study also identified a novel AAV variant with desirable biodistribution properties for targeting peripheral organs.
SARS-CoV-2 uses machinery of defense cells to induce expression of unproductive isoforms of key antiviral genes, disrupting normal protein production and immune response. The study provides fundamental information on potential targets for antiviral medications and immunomodulatory interventions.
Researchers from University of Maryland discovered RNA mechanisms that can lead to more effective and durable RNA-based drug treatments for conditions like high cholesterol, liver diseases, and cancers. The study highlighted the need to consider drug resistance when developing these treatments.
Texas A&M researchers are investigating the use of extracellular vesicles to deliver immune-suppressing proteins, potentially reducing the immune system's attack on insulin-producing beta-cells. The goal is to develop a novel treatment for type 1 diabetes, which currently has only lifelong insulin therapy as an approved option.
A Phase 1 study evaluates an individualized neoantigen therapy, showing it is well-tolerated and boosts immune activity against cancer-causing cells. The therapy induces multiple forms of T cell proliferation and sustained responses in patients with melanoma and lung cancer.
Researchers at U of T mapped the spatial distribution of long non-coding RNAs in testes, finding higher levels than previously estimated. The study suggests lncRNAs play a more significant role in male reproduction and may influence sperm development and behavior.
Scientists improve stability and bioavailability of mRNA nanocarriers using triphenylphosphonium, leading to increased protein production in tumor tissues. The TPP-based system also shows higher mRNA levels in blood after 30 minutes compared to amine-based micelles.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center discovered that the protein IRF1 can both hinder and help the body's immune response to tumors, depending on which cells it is found in. The study suggests that targeting IRF1 could enhance cancer treatment effectiveness by boosting natural antitumor immunity.
Researchers developed an innovative gene-writing technology based on R2 retrotransposons, enabling efficient and precise targeted gene integration in human cells. The en-R2Tg system achieves high gene integration specificity at the 28S rDNA safe harbor site, reducing mutagenesis risks.
Co-circulation of Mayaro and chikungunya viruses has been observed in Roraima, Brazil's northernmost state, according to a recent study. The finding highlights the need for more effective epidemiological surveillance in the region. Deforestation and human activities may facilitate transmission in urban areas.
Dr. Sanaz Memarzadeh and her team aim to improve treatment outcomes for patients with platinum-resistant ovarian cancer using adoptive T-cell therapy and natural killer cells. They hope to identify new targets and biomarkers for effective treatments.
LNP-mRNA therapy faces challenges like targeting, quality control, and safety concerns. Researchers are optimizing dosage, addressing CMC requirements, and enhancing targeting efficiency to improve therapeutic outcomes.
A recent study by Johns Hopkins Medicine reveals that the ZAK protein is a critical player in the cell's response to UV radiation damage, determining whether cells live or die. The research, published in Cell, suggests that companies developing drugs targeting ribosomes may find ZAK to be a driver of cell death across cancer types.
Protein nanocages (PNCs) are a promising system for safe and effective delivery of messenger RNAs (mRNAs). PNCs can encapsulate and protect mRNAs, facilitating efficient delivery. They offer advantages such as precise cargo encapsulation, enhanced stability, and compatibility with biological systems.
Researchers at U of T have harnessed CRISPR to efficiently and precisely control RNA splicing, enabling the systematic interrogation of gene functions and correction of splicing deficiencies in diseases. This new tool allows for targeted activation or repression of alternative exons with high specificity.
Researchers used machine learning to integrate high-throughput transcriptomic, proteomic, metabolomic, and lipidomic profiles to identify four distinct molecular profiles of Alzheimer's Disease. These profiles were associated with varying levels of cognitive function and neuropathological features.
Researchers at Weill Cornell Medicine discovered that interleukin-23 acts on group 3 innate lymphoid cells to balance pro-inflammatory effects and maintain gut health. This interaction is impaired in chronic inflammatory bowel diseases, providing new insights into the disease and potential therapeutic targets.
Researchers found that metformin increases levels of microRNAs miR-2110 and miR-132-3p, targeting genes PIK3R3 and STMN1 to slow down cancer cell growth and division. This study provides new insights into metformin's molecular mechanisms and its potential as a preventive agent for reducing cancer growth.
Researchers compiled over 100 investigators' data from more than two dozen countries, increasing human spaceflight data by 10-fold. The results revealed longer-lasting molecular and physiologic changes distinct between crew members, targeting new areas for aerospace medicine.
Researchers have developed a method to mask and regulate RNA activity and delivery using post-synthetic acylation chemistry and dynamic disulfide exchange reactions. This strategy allows for efficient RNA delivery into cells without getting trapped in lysosomes.
Researchers at the University of Toronto discovered a new RNA virus, Apocryptovirus odysseus, associated with severe inflammation in humans infected with Toxoplasma gondii. The virus is found in two hypervirulent strains of the parasite, exacerbating toxoplasmosis disease and triggering an immune response.
A team of researchers from Xi'an Jiaotong-Liverpool University has engineered a short sequence of artificial DNA to target the mutant protein p53-R175H, linked to lung, colorectal, and breast cancers. The new molecule, dp53m, inhibits cancer cell growth and increases sensitivity to chemotherapy agent cisplatin.
The Penn researchers developed an mRNA vaccine targeting a specific subtype of the H5N1 virus, which elicited strong antibody and T cell responses in mice and ferrets. Vaccinated animals also cleared the virus more rapidly and displayed fewer symptoms than unvaccinated controls.
Researchers found that miR-377 reduces MYC mRNA levels, leading to increased Bax and PTEN expression and decreased CDK4. This results in induced apoptosis, inhibited proliferation, and arrested cell cycle in prostate cancer cells.
A recent study reveals that a cellular process called transfer Ribonucleic acid (tRNA) modification influences the malaria parasite’s ability to develop resistance. This breakthrough discovery could help researchers develop new drugs to combat resistance and better tools for studying RNA modifications.
A team of scientists has developed a novel vaccine approach that induces long-lasting protective immunity against SARS-CoV-2 virus in pre-clinical models. The Clec9A-RBD antibody construct targets specific dendritic cells, leading to exceptional durability of immune responses and potential to address shortcoming of current mRNA vaccines.
Researchers at U of T have identified two compounds, diindolylmethane and diindolylethane, produced by gut bacteria that can regulate the nuclear receptor CAR, potentially treating diseases like diabetes, fatty liver disease, and small intestine ulcerative colitis.
A new mRNA cancer vaccine has been shown to trigger a vigorous immune response in both human patients and pet dogs with glioblastoma, the most aggressive form of brain cancer. The breakthrough treatment, which uses a personalized approach and novel delivery mechanism, demonstrates promising results in early clinical trials.
Researchers found a three-component signaling pathway in hepatic stellate cells that leads to collagen production and liver fibrosis. A novel RNA-based treatment, ASO, was designed to block this pathway, preventing fibrosis without side effects.
Researchers identified elevated MALAT1 levels in various blood cancers, correlating with adverse outcomes. MALAT1 promotes cancer cell proliferation, migration, invasion, and metastasis through multiple mechanisms.
A team of researchers used a rapid metagenomics technique to sequence viral RNA and DNA from blood-engorged mosquitoes collected in São Paulo city, identifying vectors, viruses, and hosts. The protocol has the potential to extend our understanding of insect genetic diversity and arbovirus transmission.
Researchers from Osaka University have discovered a way to deliver antisense oligonucleotides to their targets inside cancer cells by opening specific calcium permeable channels. The new compound, L687, promotes efficient uptake of ASO into cancer cells, suppressing target gene activity and enhancing ASO efficacy.
Researchers at UC Riverside demonstrate a new vaccine strategy targeting a common viral genome part, eliminating the need for annual booster shots. The vaccine uses small RNA molecules to boost the immune system, making it safe for babies and those with weakened immunity.
Researchers highlight the role of post-transcriptional RNA modifications in AML pathogenesis, identifying m6A and m7G regulators as potential therapeutic targets. Targeted therapies, including selective inhibitors and Traditional Chinese Medicine compounds, show promise in promoting cell differentiation and reversing AML phenotypes.